In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Stealth Biotherapeutics (MITO – Research Report), with a price target of $1.50. The company’s shares closed last Wednesday at $0.29, close to its 52-week low of $0.16.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of -12.7% and a 31.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Stealth Biotherapeutics with a $1.25 average price target.
Stealth Biotherapeutics’ market cap is currently $19.09M and has a P/E ratio of -0.32.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Newton, MA.
Read More on MITO: